Therapeutic target for protozoal diseases
Patent
·
OSTI ID:985188
- Blacksburg, VA
A novel Fasciclin Related Adhesive Protein (FRAP) from Plasmodium and related parasites is provided as a target for therapeutic intervention in diseases caused by the parasites. FRAP has been shown to play a critical role in adhesion to, or invasion into, host cells by the parasite. Furthermore, FRAP catalyzes the neutralization of heme by the parasite, by promoting its polymerization into hemozoin. This invention provides methods and compositions for therapies based on the administration of protein, DNA or cell-based vaccines and/or antibodies based on FRAP, or antigenic epitopes of FRAP, either alone or in combination with other parasite antigens. Methods for the development of compounds that inhibit the catalytic activity of FRAP, and diagnostic and laboratory methods utilizing FRAP are also provided.
- Research Organization:
- VIRGINIA POLYTECH INST/ST UNIV
- Sponsoring Organization:
- USDOE
- DOE Contract Number:
- FC36-01GO11086;
- Assignee:
- Virginia Tech Intellectual Properties, Inc. (Blacksburg, VA)
- Patent Number(s):
- 7,438,916
- Application Number:
- 11/249,355
- OSTI ID:
- 985188
- Country of Publication:
- United States
- Language:
- English
Infectivity-associated Changes in the Transcriptional Repertoire of the Malaria Parasite Sporozoite Stage
|
journal | August 2002 |
Similar Records
Multimeric antibodies from antigen-specific human IgM+ memory B cells restrict
Plasmodium
parasites
Structure-based design of a strain transcending AMA1-RON2L malaria vaccine
Journal Article
·
2021
· Journal of Experimental Medicine
·
OSTI ID:1769222
Structure-based design of a strain transcending AMA1-RON2L malaria vaccine
Journal Article
·
2023
· Nature Communications
·
OSTI ID:2423665